Che Aishah Nazariah Ismail1, Rapeah Suppian2, Che Badariah Abd Aziz1, Idris Long2. 1. 1Physiology Department, School of Medical Sciences, Universiti Sains Malaysia Health Campus, 16150 Kubang Kerian, Kelantan Malaysia. 2. 2School of Health Sciences, Universiti Sains Malaysia Health Campus, 16150 Kubang Kerian, Kelantan Malaysia.
Abstract
AIM: This study investigates the effects of minocycline (an inhibitor of microglial activation) administration on the expression level of spinal BDNF and DREAM proteins in diabetic neuropathic pain (DNP) rats. METHODS: The rats were divided into four groups (n = 16): non-diabetic control, diabetic control and diabetic rats receiving minocycline (80 μg/day or 160 μg/day). The diabetic rat model was induced by intraperitoneal injection of streptozotocin (60 mg/kg STZ). Tactile allodynia was assessed on day-0 (baseline), day-14 (pre-intervention) and day-22 (post-intervention). Minocycline at doses of 80 μg and 160 μg were given intrathecally from day-15 until day-21. On day-23, formalin test was conducted to assess nociceptive behaviour response. The spinal expression of OX-42 and level of BDNF and DREAM proteins were detected by immunohistochemistry and western blot analyses. RESULTS: Diabetes rats showed significant tactile allodynia and nociceptive behaviour. These were accompanied by augmented expression of spinal OX-42, BDNF and DREAM protein levels. Both doses of minocycline attenuated tactile allodynia and nociceptive behaviour and also suppressed the diabetic-induced increase in spinal expressions of OX-42, BDNF and DREAM proteins. CONCLUSION: This study revealed that minocycline could attenuate DNP by modulating spinal BDNF and DREAM protein expressions.
AIM: This study investigates the effects of minocycline (an inhibitor of microglial activation) administration on the expression level of spinal BDNF and DREAM proteins in diabetic neuropathic pain (DNP) rats. METHODS: The rats were divided into four groups (n = 16): non-diabetic control, diabetic control and diabetic rats receiving minocycline (80 μg/day or 160 μg/day). The diabetic rat model was induced by intraperitoneal injection of streptozotocin (60 mg/kg STZ). Tactile allodynia was assessed on day-0 (baseline), day-14 (pre-intervention) and day-22 (post-intervention). Minocycline at doses of 80 μg and 160 μg were given intrathecally from day-15 until day-21. On day-23, formalin test was conducted to assess nociceptive behaviour response. The spinal expression of OX-42 and level of BDNF and DREAM proteins were detected by immunohistochemistry and western blot analyses. RESULTS: Diabetes rats showed significant tactile allodynia and nociceptive behaviour. These were accompanied by augmented expression of spinal OX-42, BDNF and DREAM protein levels. Both doses of minocycline attenuated tactile allodynia and nociceptive behaviour and also suppressed the diabetic-induced increase in spinal expressions of OX-42, BDNF and DREAM proteins. CONCLUSION: This study revealed that minocycline could attenuate DNP by modulating spinal BDNF and DREAM protein expressions.
Authors: Hai-Ying M Cheng; Graham M Pitcher; Steven R Laviolette; Ian Q Whishaw; Kit I Tong; Lisa K Kockeritz; Teiji Wada; Nicholas A Joza; Michael Crackower; Jason Goncalves; Ildiko Sarosi; James R Woodgett; Antonio J Oliveira-dos-Santos; Mitsuhiko Ikura; Derek van der Kooy; Michael W Salter; Josef M Penninger Journal: Cell Date: 2002-01-11 Impact factor: 41.582
Authors: R J Mannion; M Costigan; I Decosterd; F Amaya; Q P Ma; J C Holstege; R R Ji; A Acheson; R M Lindsay; G A Wilkinson; C J Woolf Journal: Proc Natl Acad Sci U S A Date: 1999-08-03 Impact factor: 11.205
Authors: A Nitta; R Murai; N Suzuki; H Ito; H Nomoto; G Katoh; Y Furukawa; S Furukawa Journal: Neurotoxicol Teratol Date: 2002 Sep-Oct Impact factor: 3.763
Authors: Christina Lilliehook; Ozlem Bozdagi; Jun Yao; Manuel Gomez-Ramirez; Nikhat F Zaidi; Wilma Wasco; Sam Gandy; Anthony C Santucci; Vahram Haroutunian; George W Huntley; Joseph D Buxbaum Journal: J Neurosci Date: 2003-10-08 Impact factor: 6.167